How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses

References

• Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine. 2000;18:1436–1447.
   PubMed Web of Science ®Google Scholar
• Klasse PJ, Sanders RW, Cerutti A, et al. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses. 2012;28:1–15.
   PubMed Web of Science ®Google Scholar
• Burton DR, Poignard P, Stanfield RL, et al. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012;337:183–186.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47:401–409.
   PubMed Web of Science ®Google Scholar
• Stanley M, Lowy DR, Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006;24(Suppl. 3):S3/106–113.
   Google Scholar
• Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 2012;492:118–122.
   PubMed Web of Science ®Google Scholar
• West AP Jr., Scharf L, Scheid JF, et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell. 2014;156:633–648.
   PubMed Web of Science ®Google Scholar
• Hansen SG, Ford JC, Lewis MS, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011;473:523–527.
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–2220.
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366:1275–1286.
   PubMed Web of Science ®Google Scholar
• Burton DR, Ahmed R, Barouch DH, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe. 2012;12:396–407.
   PubMed Web of Science ®Google Scholar
• Klasse PJ, Moore JP. Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines. Retrovirology. 2012;9:80.
   PubMed Web of Science ®Google Scholar
• Ward KNju87, Dhaliwal W, Ashworth KL, et al. Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody. J Med Virol. 1994;43:367–372.
   PubMed Web of Science ®Google Scholar
• Hedman K, Seppala I. Recent rubella virus infection indicated by a low avidity of specific IgG. J Clin Immunol. 1988;8:214–221.
   PubMed Web of Science ®Google Scholar
• Soderlund M, Brown CS, Cohen BJ, et al. Accurate serodiagnosis of B19 parvovirus infections by measurement of IgG avidity. J Infect Dis. 1995;171:710–713.
   PubMed Web of Science ®Google Scholar
• Ward KN, Gray JJ, Joslin ME, et al. Avidity of IgG antibodies to human herpesvirus-6 distinguishes primary from recurrent infection in organ transplant recipients and excludes cross-reactivity with other herpesviruses. J Med Virol. 1993;39:44–49.
   PubMed Web of Science ®Google Scholar
• Lutz E, Ward KN, Gray JJ. Maturation of antibody avidity after primary human cytomegalovirus infection is delayed in immunosuppressed solid organ transplant patients. J Med Virol. 1994;44:317–322.
   PubMed Web of Science ®Google Scholar
• Monsalvo AC, Batalle JP, Lopez MF, et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med. 2011;17:195–199.
   PubMed Web of Science ®Google Scholar
• Polack FP, Hoffman SJ, Crujeiras G, et al. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med. 2003;9:1209–1213.
   PubMed Web of Science ®Google Scholar
• Gassmann C, Bauer G. Avidity determination of IgG directed against tick-borne encephalitis virus improves detection of current infections. J Med Virol. 1997;51:242–251.
   PubMed Web of Science ®Google Scholar
• Hedman K, Vaheri A, Brummer-Korvenkontio M. Rapid diagnosis of hantavirus disease with an IgG-avidity assay. Lancet. 1991;338:1353–1356.
   PubMed Web of Science ®Google Scholar
• Wreghitt TG, Gray JJ, Aloyisus S, et al. Antibody avidity test for recent infection with hepatitis C virus. Lancet. 1990;335:789.
   PubMed Web of Science ®Google Scholar
• Cole KS, Alvarez M, Elliott DH, et al. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. Virology. 2001;290:59–73.
   PubMed Web of Science ®Google Scholar
• Wei X, Liu X, Dobbs T, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses. 2010;26:61–71.
   PubMed Web of Science ®Google Scholar
• Narita M, Matsuzono Y, Takekoshi Y, et al. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G. Clin Diagn Lab Immunol. 1998;5:799–803.
   PubMedGoogle Scholar
• Narita M, Yamada S, Matsuzono Y, et al. Immunoglobulin G avidity testing in serum and cerebrospinal fluid for analysis of measles virus infection. Clin Diagn Lab Immunol. 1996;3:211–215.
   PubMedGoogle Scholar
• Fox JL, Hazell SL, Tobler LH, et al. Immunoglobulin G avidity in differentiation between early and late antibody responses to West Nile virus. Clin Vaccine Immunol. 2006;13:33–36.
   PubMed Web of Science ®Google Scholar
• Hearty S, Conroy PJ, Ayyar BV, et al. Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends. Expert Rev Vaccines. 2010;9:645–664.
   PubMed Web of Science ®Google Scholar
• Yasmeen A, Ringe R, Derking R, et al. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology. 2014;11:41.
   PubMed Web of Science ®Google Scholar
• Sela-Culang I, Kunik V, Ofran Y. The structural basis of antibody-antigen recognition. Front Immunol. 2013;4:302.
   PubMed Web of Science ®Google Scholar
• Underwood PA. Problems and pitfalls with measurement of antibody affinity using solid phase binding in the ELISA. J Immunol Methods. 1993;164:119–130.
   PubMed Web of Science ®Google Scholar
• Underwood PA, Steele JG, Dalton BA. Effects of polystyrene surface chemistry on the biological activity of solid phase fibronectin and vitronectin, analysed with monoclonal antibodies. J Cell Sci. 1993;104(Pt 3):793–803.
   PubMed Web of Science ®Google Scholar
• Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol. 2006;6:231–243.
   PubMed Web of Science ®Google Scholar
• Butler JE, Feldbush TL, McGivern PL, et al. The enzyme-linked immunosorbent assay (ELISA): a measure of antibody concentration or affinity. Immunochemistry. 1978;15:131–136.
   PubMedGoogle Scholar
• Engvall E, Perlmann P. Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J Immunol. 1972;109:129–135.
   PubMed Web of Science ®Google Scholar
• Katz FE, Steward MW. Studies on the genetic control of antibody affinity: the independent control of antibody levels and affinity in Biozzi mice. J Immunol. 1976;117:477–479.
   PubMed Web of Science ®Google Scholar
• Klasse PJ, Sattentau QJ. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol. 2002;83:2091–2108.
   PubMed Web of Science ®Google Scholar
• Edgington TS. Dissociation of antibody from erythrocyte surfaces by chaotropic ions. J Immunol. 1971;106:673–680.
   PubMed Web of Science ®Google Scholar
• Pullen GR, Fitzgerald MG, Hosking CS. Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods. 1986;86:83–87.
   PubMed Web of Science ®Google Scholar
• Jungwirth P, Cremer PS. Beyond Hofmeister. Nat Chem. 2014;6:261–263.
   PubMed Web of Science ®Google Scholar
• Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med. 2011;3:85ra48.
   PubMed Web of Science ®Google Scholar
• Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004;5:233–236.
   PubMed Web of Science ®Google Scholar
• Gordon SN, Doster MN, Kines RC, et al. Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia. J Immunol. 2014;193:6172–6183.
   PubMed Web of Science ®Google Scholar
• Lai L, Kwa S, Kozlowski PA, et al. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis. 2011;204:164–173.
   PubMed Web of Science ®Google Scholar
• Lai L, Vodros D, Kozlowski PA, et al. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology. 2007;369:153–167.
   PubMed Web of Science ®Google Scholar
• Letvin NL, Rao SS, Montefiori DC, et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med. 2011;3:81ra36.
   PubMed Web of Science ®Google Scholar
• Pegu P, Vaccari M, Gordon S, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol. 2013;87:1708–1719.
   PubMed Web of Science ®Google Scholar
• Ross TM, Xu Y, Green TD, et al. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses. 2001;17:829–835.
   PubMed Web of Science ®Google Scholar
• Xiao P, Patterson LJ, Kuate S, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J Virol. 2012;86:4644–4657.
   PubMed Web of Science ®Google Scholar
• Zhao J, Lai L, Amara RR, et al. Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol. 2009;83:4102–4111.
   PubMed Web of Science ®Google Scholar
• Xiao P, Zhao J, Patterson LJ, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol. 2010;84:7161–7173.
   PubMed Web of Science ®Google Scholar
• Gupta S, Clark ES, Termini JM, et al. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. J Virol. 2015. DOI:10.1128/JVI.02904-14.
   Web of Science ®Google Scholar
• Richmond JF, Lu S, Santoro JC, et al. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol. 1998;72:9092–9100.
   PubMed Web of Science ®Google Scholar
• Barlow DJ, Edwards MS, Thornton JM. Continuous and discontinuous protein antigenic determinants. Nature. 1986;322:747–748.
   PubMed Web of Science ®Google Scholar
• Atassi MZ. Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking of protein binding sites. Eur J Biochem. 1984;145:1–20.
   PubMedGoogle Scholar
• Berzofsky JA. Intrinsic and extrinsic factors in protein antigenic structure. Science. 1985;229:932–940.
   PubMed Web of Science ®Google Scholar
• Goudsmit J, Meloen RH, Brasseur R. Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe. Intervirology. 1990;31:327–338.
   PubMed Web of Science ®Google Scholar
• Klasse PJ, Pipkorn R, Blomberg J. A cluster of continuous antigenic structures in the transmembrane protein of HIV-1: individual patterns of reactivity in human sera. Mol Immunol. 1991;28:613–622.
   PubMed Web of Science ®Google Scholar
• Laver WG, Air GM, Webster RG, et al. Epitopes on protein antigens: misconceptions and realities. Cell. 1990;61:553–556.
   PubMed Web of Science ®Google Scholar
• Rosen O, Chill J, Sharon M, et al. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization. Biochemistry. 2005;44:7250–7258.
   PubMed Web of Science ®Google Scholar
• Julien JP, Cupo A, Sok D, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013;342:1477–1483.
   PubMed Web of Science ®Google Scholar
• Lyumkis D, Julien JP, De Val N, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science. 2013;342:1484–1490.
   PubMed Web of Science ®Google Scholar
• Checkley MA, Luttge BG, Freed EO. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol. 2011;410:582–608.
   PubMed Web of Science ®Google Scholar
• Klasse PJ. Structural biology. A new bundle of prospects for blocking HIV-1 entry. Science. 2013;341:1347–1348.
   PubMed Web of Science ®Google Scholar
• Weiss RA. Thirty years on: HIV receptor gymnastics and the prevention of infection. BMC Biol. 2013;11:57.
   PubMed Web of Science ®Google Scholar
• Klasse PJ. The molecular basis of HIV entry. Cell Microbiol. 2012;14:1183–1192.
   PubMed Web of Science ®Google Scholar
• Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015;16:571–576.
   PubMed Web of Science ®Google Scholar
• Moore JP, Dd H. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol. 1993;67:863–875.
   PubMed Web of Science ®Google Scholar
• Klein F, Mouquet H, Dosenovic P, et al. Antibodies in HIV-1 vaccine development and therapy. Science. 2013;341:1199–1204.
   PubMed Web of Science ®Google Scholar
• Simek MD, Rida W, Priddy FH, et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol. 2009;83:7337–7348.
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Klein RM, Daniels MG, et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol. 2010;84:1631–1636.
   PubMed Web of Science ®Google Scholar
• Mikell I, Sather DN, Kalams SA, et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011;7:e1001251.
   PubMed Web of Science ®Google Scholar
• Piantadosi A, Panteleeff D, Blish CA, et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol. 2009;83:10269–10274.
   PubMed Web of Science ®Google Scholar
• Medina-Ramirez M, Sanders RW, Klasse PJ. Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development? Expert Rev Vaccines. 2014;13:449–452.
   PubMed Web of Science ®Google Scholar
• Klein F, Diskin R, Scheid JF, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 2013;153:126–138.
   PubMed Web of Science ®Google Scholar
• Alexander MR, Ringe R, Sanders RW, et al. What do chaotrope-based avidity assays for antibodies to HIV-1 envelope glycoproteins measure? J Virol. 2015. DOI:10.1128/JVI.00320-15.
   Web of Science ®Google Scholar
• Binley JM, Arshad H, Fouts TR, et al. An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 1997;13:1007–1015.
   PubMed Web of Science ®Google Scholar
• Curtis KA, Kennedy MS, Luckay A, et al. Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2011;57:355–362.
   PubMed Web of Science ®Google Scholar
• Duong YT, Qiu M, Ak D, et al. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One. 2012;7:e33328.
   PubMed Web of Science ®Google Scholar
• Dimitrov JD, Lacroix-Desmazes S, Kaveri SV. Important parameters for evaluation of antibody avidity by immunosorbent assay. Anal Biochem. 2011;418:149–151.
   PubMed Web of Science ®Google Scholar
• Hardie G, Van Regenmortel MH. Isolation of specific antibody under conditions of low ionic strength. J Immunol Methods. 1977;15:305–314.
   PubMed Web of Science ®Google Scholar
• Kamoun PP. Denaturation of globular proteins by urea: breakdown of hydrogen or hydrophobic bonds? Trends Biochem Sci. 1988;13:424–425.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cremer PS. Interactions between macromolecules and ions: the Hofmeister series. Curr Opin Chem Biol. 2006;10:658–663.
   PubMed Web of Science ®Google Scholar
• Baldwin RL. How Hofmeister ion interactions affect protein stability. Biophys J. 1996;71:2056–2063.
   PubMed Web of Science ®Google Scholar
• Andersson K, Choulier L, Hamalainen MD, et al. Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space. J Mol Recognit. 2001;14:62–71.
   PubMed Web of Science ®Google Scholar
• Choulier L, Andersson K, Hamalainen MD, et al. QSAR studies applied to the prediction of antigen-antibody interaction kinetics as measured by BIACORE. Protein Eng. 2002;15:373–382.
   PubMedGoogle Scholar
• Hall TJ, Heckel C. Thiocyanate elution estimation of relative antibody affinity. J Immunol Methods. 1988;115:153–155.
   PubMed Web of Science ®Google Scholar
• Eisen HN, Chakraborty AK. Evolving concepts of specificity in immune reactions. Proc Natl Acad Sci U S A. 2010;107:22373–22380.
   PubMed Web of Science ®Google Scholar
• Manivel V, Sahoo NC, Salunke DM, et al. Maturation of an antibody response is governed by modulations in flexibility of the antigen-combining site. Immunity. 2000;13:611–620.
   PubMed Web of Science ®Google Scholar
• Wedemayer GJ, Patten PA, Wang LH, et al. Structural insights into the evolution of an antibody combining site. Science. 1997;276:1665–1669.
   PubMed Web of Science ®Google Scholar
• Zimmermann J, Oakman EL, Thorpe IF, et al. Antibody evolution constrains conformational heterogeneity by tailoring protein dynamics. Proc Natl Acad Sci U S A. 2006;103:13722–13727.
   PubMed Web of Science ®Google Scholar
• Julien JP, Lee JH, Cupo A, et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A. 2013;110:4351–4356.
   PubMed Web of Science ®Google Scholar
• Derking R, Ozorowski G, Sliepen K, et al. Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS Pathog. 2015;11:e1004767.
   PubMed Web of Science ®Google Scholar
• Absolom DR, Van Oss CJ. The nature of the antigen-antibody bond and the factors affecting its association and dissociation. CRC Crit Rev Immunol. 1986;6:1–46.
   PubMedGoogle Scholar
• Van Oss CJ, Good RJ, Chaudhury MK. Nature of the antigen-antibody interaction. Primary and secondary bonds: optimal conditions for association and dissociation. J Chromatogr. 1986;376:111–119.
   PubMed Web of Science ®Google Scholar
• Do Kwon Y, Pancera M, Acharya P, et al., et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol. 2015;22:522–531.
   PubMed Web of Science ®Google Scholar
• Munro JB, Gorman J, Ma X, et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science. 2014;346:759–763.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342:592–598.
   PubMed Web of Science ®Google Scholar
• Haim H, Salas I, McGee K, et al. Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency. Cell Host Microbe. 2013;14:547–558.
   PubMed Web of Science ®Google Scholar
• Karlsson R, Michaelsson A, Mattsson L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods. 1991;145:229–240.
   PubMed Web of Science ®Google Scholar
• Sather DN, Carbonetti S, Malherbe DC, et al. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1. J Virol. 2014;88:12968–12981.
   PubMed Web of Science ®Google Scholar
• Abdiche Y, Malashock D, Pinkerton A, et al. Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Anal Biochem. 2008;377:209–217.
   PubMed Web of Science ®Google Scholar
• Khurana S, Coyle EM, Verma S, et al. H5 N-terminal beta sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine. Vaccine. 2014;32:6421–6432.
   PubMed Web of Science ®Google Scholar
• VanCott TC, Bethke FR, Polonis VR, et al. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol. 1994;153:449–459.
   PubMed Web of Science ®Google Scholar
• Richalet-Secordel PM, Rauffer-Bruyere N, Christensen LL, et al. Concentration measurement of unpurified proteins using biosensor technology under conditions of partial mass transport limitation. Anal Biochem. 1997;249:165–173.
   PubMed Web of Science ®Google Scholar
• Zeder-Lutz G, Benito A, Van Regenmortel MH. Active concentration measurements of recombinant biomolecules using biosensor technology. J Mol Recognit. 1999;12:300–309.
   PubMed Web of Science ®Google Scholar
• Greenspan NS. Affinity, complementarity, cooperativity, and specificity in antibody recognition. Curr Top Microbiol Immunol. 2001;260:65–85.
   PubMed Web of Science ®Google Scholar
• Alexander MR, Sanders RW, Moore JP, et al. Virion aggregation by neutralizing and nonneutralizing antibodies to the HIV-1 envelope glycoprotein. AIDS Res Hum Retroviruses. 2015. DOI:10.1089/AID.2015.0050.
   PubMed Web of Science ®Google Scholar
• Schofield DJ, Dimmock NJ. Determination of affinities of a panel of IgGs and Fabs for whole enveloped (influenza A) virions using surface plasmon resonance. J Virol Methods. 1996;62:33–42.
   PubMed Web of Science ®Google Scholar
• Klein JS, Bjorkman PJ. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog. 2010;6:e1000908.
   PubMed Web of Science ®Google Scholar
• Galimidi RP, Klein JS, Politzer MS, et al. Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell. 2015;160:433–446.
   PubMed Web of Science ®Google Scholar
• Batista FD, Neuberger MS. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity. 1998;8:751–759.
   PubMed Web of Science ®Google Scholar
• Van Regenmortel MH. Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition. J Mol Recognit. 2014;27:627–639.
   PubMed Web of Science ®Google Scholar
• James LC, Roversi P, Tawfik DS. Antibody multispecificity mediated by conformational diversity. Science. 2003;299:1362–1367.
   PubMed Web of Science ®Google Scholar
• Mouquet H, Scheid JF, Zoller MJ, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010;467:591–595.
   PubMed Web of Science ®Google Scholar
• Mouquet H, Warncke M, Scheid JF, et al. Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci U S A. 2012;109:875–880.
   PubMed Web of Science ®Google Scholar
• Dunlop DC, Bonomelli C, Mansab F, et al. Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology. 2010;20:812–823.
   PubMed Web of Science ®Google Scholar
• Sok D, Doores KJ, Briney B, et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med. 2014;6:236ra263.
   Web of Science ®Google Scholar
• Ketas TJ, Holuigue S, Matthews K, et al. Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology. 2012;422:22–36.
   PubMed Web of Science ®Google Scholar
• McCoy LE, Falkowska E, Doores KJ, et al. Incomplete neutralization and deviation from sigmoidal neutralization curves for HIV broadly neutralizing monoclonal antibodies. PLoS Pathog. 2015;11:e1005110.
   PubMed Web of Science ®Google Scholar
• Parren PW, Mondor I, Naniche D, et al. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol. 1998;72:3512–3519.
   PubMed Web of Science ®Google Scholar
• Pugach P, Ozorowski G, Cupo A, et al. A native-like SOSIP.664 trimer based on an HIV-1 subtype B Env gene. J Virol. 2015;89:3380–3395.
   PubMed Web of Science ®Google Scholar
• Sanders RW, Derking R, Cupo A, et al. A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013;9:e1003618.
   PubMed Web of Science ®Google Scholar
• Corti D, Lanzavecchia A. Efficient methods to isolate human monoclonal antibodies from memory b cells and plasma cells. Microbiol Spectr. 2014;2:1–9.
   PubMedGoogle Scholar